Pharmacoeconomic analysis of levilimab use as rheumatoid arthritis therapy in the healthcare system of the Russian Federation

Objective. To assess the economic feasibility of using levilimab (LVL) for the treatment of rheumatoid arthritis (RA) compared with other interleukin-6 inhibitors (IL-6i) currently used in the healthcare system of the Russian Federation.
Material and methods. A cost-minimization analysis was performed according to the approved dosing regimens registered in the Russian Federation for all IL-6i used in RA therapy. The possibility of a reduced dosing regimen for LVL and olokizumab (OKZ), as indicated in the summary of product characteristics, was also considered.
Results and discussion. LVL showed the lowest therapy costs for RA starting from the second year and beyond, compared with other IL-6i, assuming comparable clinical efficacy according to ACR50 and DAS28 criteria. Treatment costs for LVL in the second and subsequent years were 11.2% lower than for OKZ, 26.7% lower than for tocilizumab (TCZ) for intravenous use, and 30.9% lower than for TCZ for subcutaneous use.
Conclusion. LVL therapy in patients with RA is an economically reasonable given its two dosing regimens. The use of LVL can reduce healthcare system expenditures over a 2-year and longer horizon while maintaining comparable clinical efficacy to other IL-6i, thereby enabling treatment of a larger number of patients.

1. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: problems of remission and resistance to therapy. Nauchno-prakticheskaya revmatologiya. 2018;56(3):263-71. (In Russ.).

2. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021 May;41(5):863-877. doi: 10.1007/s00296-020-04731-0.

3. Lila AM, Dreval' RO, Shipitsyn VV. Assessment of the organization of medical care and drug provision for rheumatic diseases and the socio-economic burden of these diseases in the Russian Federation. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):112-119. (In Russ.).

4. Hsieh PH, Wu O, Geue C, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020 Jun;79(6):771-777. doi: 10.1136/annrheumdis-2019-216243.

5. Nasonov EL, editor. Rheumatology: Russian clinical guidelines. Moscow: GEOTAR-Media; 2017: 464 p.

6. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356.

7. Sokolova VD, Mladov VV, Sableva NA, Tolkacheva DG. The effectiveness of biological and targeted synthetic basic anti-inflammatory drugs registered in the Russian Federation for the treatment of adult patients with active rheumatoid arthritis: a systematic review and a network meta-analysis. Meditsinskie tekhnologii. Otsenka i vybor. 2022;44(1):50-64.

8. Karateev DE, Luchikhina EL. Interleukin 6 inhibitors in the treatment of rheumatoid arthritis. Effektivnaya farmakoterapiya. 2022;18(8):16-21. (In Russ.).

9. Mazurov VI, Nasonov EL, Lila AM, et al. Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR. Dokl Biochem Biophys. 2024 Oct;518(1):403-416. doi: 10.1134/S1607672924701072.

10. Shesternya PA, Zagrebneva AI, Antipova OV, et al.. Primenenie pryamogo ingibitora interleikina 6 olokizumaba v terapii revmatoidnogo artrita: dannye real'noi klinicheskoi praktiki. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2025;19(2):39-49. (In Russ.). doi: 10.14412/1996-7012-2025-2-39-49

11. Zyryanov SK, Cheberda AE, Belousov DYu. Pharmacoeconomic analysis of the use of tocilizumab in subcutaneous injection in patients with rheumatoid arthritis. Kachestvennaya klinicheskaya praktika. 2015;(4):33-41. (In Russ.).

12. Kolbin AS, Kurylev AA, Mishinova SA, et al. Pharmacoeconomic analysis of tocilizumab in the treatment of patients with rheumatoid arthritis and juvenile arthritis with systemic onset. Kachestvennaya klinicheskaya praktika. 2020;(1):23-34. (In Russ.).